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Abstract
New treatments are needed to protect the myocardium against the detrimental effects of acute ischaemia/reperfusion (IR) injury following an acute myocardial infarction (AMI), in order to limit myocardial infarct (MI) size, preserve cardiac function
and prevent the onset of heart failure (HF). Given the critical role of mitochondria in
energy production for cardiac contractile function, prevention of mitochondrial dysfunction during acute myocardial IRI may provide novel cardioprotective strategies. In
this regard, the mitochondrial fusion and fissions proteins, which regulate changes in
mitochondrial morphology, are known to impact on mitochondrial quality control by
modulating mitochondrial biogenesis, mitophagy and the mitochondrial unfolded protein response. In this article, we review how targeting these inter-related processes
may provide novel treatment targets and new therapeutic strategies for reducing MI
size, preventing the onset of HF following AMI.
KEYWORDS

acute myocardial ischaemia/reperfusion injury, cardioprotection, mitochondrial morphology,
mitochondrial unfolded protein response, mitophagy cardioprotection
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by mitophagy. In contrast, mitochondrial fusion enables the replen-

1 | I NTRO D U C TI O N

ishment of damaged mitochondrial DNA and facilitates intracellular
energy distribution. A brief overview of these mitochondrial shaping

Acute myocardial infarction (AMI) and the heart failure (HF) that

proteins is given here, with the main focus being on their roles in

can follow are among the leading causes of death and disability

acute myocardial IRI, and as potential therapeutic targets for acute

worldwide. Although mortality following AMI is on the decline,

cardioprotection.

the prevalence and severity of HF is rising. Therefore, new treat-

Mitochondrial fission involves the division of a single mitochon-

ments are required to protect the myocardium against the detri-

drion into 2 individual fragmented and disconnected mitochondria

mental effects of acute ischaemia/reperfusion (IR) injury in order

by the fission proteins, dynamin-related protein 1 (Drp1), 6 human

to reduce myocardial infarct (MI) size, preserve left ventricular (LV)

fission protein 1 (hFis1),7 mitochondrial fission factor (Mff) 8 and

1

function and prevent the onset of HF. Maintenance of healthy

the mitochondrial dynamics proteins of 49 kD (MiD49) and 51 kD

mitochondria is of critical importance, given the high energy de-

(MiD51).9,10 During mitochondrial fission, cytosolic Drp1 translo-

mands required for normal cardiac contractile function. 2 Under

cates to the outer mitochondrial membrane (OMM) where it binds

conditions of energy stress such as experienced during acute

to the OMM proteins Mff, MiD49, MiD51 and possibly hFis1, at

myocardial ischaemia/reperfusion injury (IRI) following AMI, dam-

pre-constricted sites marked out by contact with endoplasmic

aged mitochondria generate less ATP and produce reactive oxygen

reticulum (ER).11 Actin polymerization through the ER-localized

species (ROS) that are detrimental to cell survival. As such, new

inverted formin 2 (INF2) protein has been shown to mediate the

therapies that are able to preserve mitochondrial function during

mitochondrial pre-constriction process.12,13 Drp1 then oligomer-

acute myocardial IRI may provide novel strategies for cardiopro-

izes and forms a helical structure at the site of pre-constriction,

tection. 2 The mitochondrial fusion and fission proteins have been

which encircles and constricts the mitochondrion further, and

shown to play critical roles in several processes related to mito-

cleaves the mitochondrion into 2 individual mitochondria in a

chondrial quality control including mitochondrial biogenesis, mi-

GTP-dependent manner.

tophagy and the unfolded protein response (UPR). Mitochondrial

A number of post-translational modifications have been shown to

fission is required to selectively remove damaged mitochondria by

regulate Drp1 function in terms of its subcellular localization and pro-

mitophagy (which are then replaced by mitochondrial biogenesis),

tein-protein interactions. These include phosphorylation, ubiquiti-

and mitochondrial fusion allows fragmented mitochondria which

nation, conjugation of small ubiquitin-like modifier (SUMO) proteins

are still viable to re-enter the mitochondrial network (reviewed

(SUMOylation), S-nitrosylation, O-linked-N-acetyl-glucosamine gly-

in Refs 2-4). The mitochondrial UPR is a cytoprotective signalling

cosylation (O-GlcNAcylation) and most recently acetylation14 (re-

pathway triggered by the mitochondrial accumulation of toxic un-

viewed in Ref. 15). Fragmented mitochondria, which have undergone

5

folded proteins under conditions of cellular stress. In this article,

fission, have been visualized by electron microscopy of fixed adult

we review how targeting these inter-related processes related to

cardiomyocytes in a number of different cardiac diseases including

mitochondrial quality control may provide novel treatment targets

acute myocardial IRI,16 myocarditis,17 stroke,18 doxorubicin cardio-

and new therapeutic strategies for reducing MI size and prevent-

toxicity,19 sepsis-related cardiomyopathy, 20 post-AMI cardiomyop-

ing HF following AMI.

athy21 and diabetic cardiomyopathy. 22 In this article, we focus on
the role of the mitochondrial fission proteins as potential therapeutic

2 | M ITO C H O N D R I A L M O R PH O LO G Y

targets for cardioprotection against acute myocardial IRI.
Mitochondrial fusion is characterized by the tethering of two
adjacent mitochondria via the OMM fusion GTPase proteins, mito-

Mitochondria are dynamic organelles, constantly changing their

fusin 1 (Mfn1)23 and mitofusin 2 (Mfn2), 24 which then mediate fu-

morphology or shape between a fragmented disconnected phe-

sion of the OMMs in a GTP-dependent manner. Subsequently, the

notype by undergoing fission, and an elongated interconnected

inner mitochondrial membrane (IMM) fusion GTPase protein, optic

morphology by undergoing fusion, processes which are coordi-

atrophy 1 (OPA1), 25,26 mediates fusion of the IMMs resulting in shar-

nated by the mitochondrial fission and fusion proteins, respectively

ing of mitochondrial matrix material, and the formation of a single

(Figure 1) (reviewed in Refs 2-4). Mitochondrial fission is essential

elongated mitochondrion. Importantly, Mfn2 has been reported to

for cell division and is required to remove damaged mitochondria

have a number of non-fusion-related functions including tethering

|
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F I G U R E 1 Mitochondrial fission and fusion proteins as targets for cardioprotection. Mitochondrial fission induced by acute myocardial
ischaemia/reperfusion injury can be targeted by mdivi-1 and Drpitor, pharmacological inhibitors of Drp1 and P110, a peptide inhibitor of the
interaction between Drp1 and hFis1 to confer cardioprotection. A number of other factors (such as SB203580, PKA activators, succinate,
erythropoietin and melatonin) have also been shown to confer cardioprotection by targeting the fusion and fission proteins. Inset upper box:
This scheme shows the mitochondrial fission machinery, comprising Drp1 and its outer mitochondrial membrane receptors, MiD49/MiD51,
Mff and hFis1. Pre-constriction by the endoplasmic reticulum (ER) via INF2, actin and Spire1C initiates the Drp1-driven mitochondrial fission
process. Inset lower box: This scheme shows the pleiotropic non-fusion effect of Mfn2 in tethering mitochondria to the ER

ER to mitochondria, 27 mediating mitophagy28 and cellular autoph29

of their proteins levels and protein-protein interactions—these in-

(Figures 2 and

clude phosphorylation (in Mfn1, Mfn2 and OPA1), acetylation (in

3). Similarly, OPA1 has been demonstrated to play several pleiotro-

Mfn1, Mfn2 and OPA1), methylation (in Mfn1 and OPA1), and ubiq-

pic non-fusion roles related to its effects on cristae remodelling the

uitination (in Mfn1, Mfn2 and OPA1) (reviewed in Ref. 15). The reg-

consequences of which are to regulate mitochondrial cytochrome

ulation of OPA1 has an added layer of complexity given that there

agy,

and contributing to the stress-related UPR

30

release

31

and to improve mitochondrial respiratory efficiency by fa-

are 8 splice variants (in humans), and proteolytic processing by mi-

cilitating the assembly of electron transport supercomplexes.32 In

tochondrial proteases, YME1L and OMA1, generates several com-

addition, OPA1 has been shown to stabilize mitochondrial cristae

binations of IMM-anchored long forms of OPA1 (termed L-OPA1)

shape and favour ATP synthase oligomerization and needs ATP syn-

which mediate IMM fusion, and soluble short forms of OPA1 within

thase to protect mitochondria from stress-induced respiratory chain

the mitochondrial matrix (termed S-OPA1), which contribute to mi-

inhibition.33 Differentiating the pro-fusion roles of Mfn2 and OPA1

tochondrial bioenergetics and cristae remodelling (reviewed in Ref.

from their non-fusion roles can be quite challenging and needs to be

26). Reduced levels of cardiomyocyte Mfn2 and OPA1 have been

taken into consideration when investigating their roles in the con-

observed in a number of cardiac diseases including left ventricular

text of acute myocardial IRI and cardioprotection, where both their

hypertrophy,34 post-AMI cardiomyopathy, 21,35 myocarditis36 and di-

pro-fusion and non-fusion roles may be important.

abetic cardiomyopathy.37 In this article, we focus on the role of the

A number of post-translational modifications have been shown
to regulate the functions of mitochondrial fusion proteins in terms

mitochondrial fusion proteins as potential therapeutic targets for
cardioprotection against acute myocardial IRI.

6574
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F I G U R E 2 Mitophagy as a target for cardioprotection. The mitochondrial fusion and fission comments have been demonstrated to
participate in 2 different mitophagy pathways—(A) the PINK-Parkin mitophagy pathway and (B) the Ulk1 mitophagy pathway (modified from
Ref. 121)

2.1 | Relevance of mitochondrial fission and fusion
proteins to the adult heart

been provided using confocal microscopy imaging of matrix-targeted
photoactivatable green fluorescent protein of whole rat hearts.40-42
These studies demonstrated rapid content mixing events between

In adult cardiomyocytes, mitochondria are distributed in 3 main lo-

adjacent organelles, and slower events between both neighbour-

cations: intermyofibrillar spaces, where they are densely packed and

ing and distant mitochondria, indicative of fusion activity and an

mainly provide energy for contractile function (interfibrillar mito-

interconnected mitochondrial network in adult ventricular cardio-

chondria), just beneath the plasma membrane, where they provide

myocytes. Interestingly, mitochondrial fusion activity was shown to

energy for the sarcolemmal ion channels (subsarcolemmal mitochon-

decrease with culturing the isolated cardiomyocytes due to a decline

dria), and around the nucleus, where they provide energy for nuclear

in calcium oscillations/contractile activity,42 such that the fusion

38

Because most adult car-

events are slow, with studies showing that the mitochondrial GFP

diac mitochondria are fragmented in morphology, and their move-

signal takes about 10 hours to spread to the entire population of mi-

ment is restricted at these 3 locations, the physiological relevance of

tochondria in adult cardiomyocytes.41 These findings raise the pos-

mitochondrial morphology and dynamics in the adult cardiomyocyte

sibility that mitochondrial fusion may actually occur at much faster

has been questioned. However, recent studies have shown that the

rates in the intact contracting heart.

transcription (perinuclear mitochondria).

mitochondrial fission and fusion proteins are expressed in the heart

Deletion of cardiomyocyte Drp1 in the early post-natal period

and are essential for normal foetal cardiac development, as their ge-

resulted in mitochondrial enlargement, increased mitochondrial in-

netic ablation is embryonically lethal (reviewed in Refs 2-4). Post-

terconnectivity, decreased mitochondrial respiration, defective mi-

natally, they are also required for normal cardiac development and

tophagy and a lethal cardiomyopathy at day 7-10 of the post-natal

contractile function, as hearts deficient in these proteins develop a

period.43,44 Similarly, cardiomyocyte-specific ablation of Drp1 in

severe dilated cardiomyopathy (reviewed in Ref. 2-4).

adult mice resulted in a severe cardiomyopathy 4 weeks later when

Based on the time course over which fusion-defective mitochon-

compared to wild-type mice with LV dilatation, reduced LV function,

drial size decreases in adult mice deficient in both Mfn1 and Mfn2,

cardiomyocyte hypertrophy, myocardial fibrosis, increased apopto-

it has been estimated that one mitochondrial fusion/fission cycle in

sis, mitochondrial enlargement, impaired mitochondrial respiratory

adult mouse hearts occurs approximately every 16 days.39 More di-

function, increased mitochondrial calcium and ROS, and enhanced

rect evidence of mitochondrial fusion in adult cardiomyocytes has

susceptibility to mitochondrial permeability transition pore (MPTP)

|
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F I G U R E 3 The mitochondrial unfolded
protein response and cardioprotection.
Schematic model of the mitochondrial
unfolded protein response (UPRmt).
Nicotinamide ribose, ischaemic
preconditioning (IPC), oligomycin and
doxycycline are therapeutic strategies
that have been shown to reduce acute
myocardial ischaemia/reperfusion injury
(IRI) by enhancing the UPRmt, and Mfn2
has been shown to play a key role in the
UPR

opening.45-47 Genetic ablation of Mff in mice has been shown to in-

effect of their deletion in the adult heart is not known, and needs

duce a lethal dilated cardiomyopathy at 13 weeks associated with

to be investigated.

increased heterogeneity in mitochondrial shape and abundance,

With respect to the mitochondrial fusion proteins, cardiomyo-

perturbed mitochondrial respiratory function, increased myocardial

cyte-specific deletion of Mfn2 resulted in a mild cardiac pheno-

apoptosis and interstitial fibrosis.48 Interestingly, this effect was re-

type with modest LVH, mild LV systolic dysfunction, no change

versed if either one of the mitochondrial fusion proteins, Mfn1 or

in mitochondrial respiratory function and unexpected changes in

Mfn2, were also deleted suggesting that the pro-fusion effect of Mff

mitochondrial morphology and MPTP opening susceptibility, with

ablation requires the presence of one of the mitofusins. This finding

pleomorphic and enlarged subsarcolemmal (but not interfibrillar)

also supports the notion that restoring the balance in mitochondrial

mitochondria, and resistance to MPTP opening.49 Interestingly, the

fission and fusion in the heart can normalize cardiac function.

48

With

effect of Mfn2 ablation on mitochondrial morphology in neonatal

regard to the mitochondrial fission proteins, MiD49 and MiD51, ge-

rat cardiomyocytes was as expected, with mitochondrial fragmen-

netic ablation of these proteins is embryonically lethal,10 but the

tation and increased susceptibility to MPTP opening, suggesting

6576
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cell-specific effects on mitochondrial morphology and MPTP opening.

49

Drp1 reduces the propensity for MPTP opening is not clear, but may

In addition, to having enlarged mitochondria, Mfn2-deficient

relate to the accumulation of factors known to induce MPTP open-

cardiomyocytes have also being shown by 3D electron microscopy

ing such as mitochondrial calcium overload, ROS production and rel-

to have fewer mitochondria-junctional sarcoplasmic reticulum (SR)

ative ATP depletion. In contrast, it has been postulated that ablation

contacts, and an increase in the distance between mitochondria

of the outer mitochondrial membrane mitofusin proteins rendered

50

cardiac mitochondria resistant to MPTP opening because of their

Overexpression of cardiomyocyte-specific Mfn2 in the adult heart

potential role in OMM remodelling, which may be associated with

had a very mild phenotype with minor mitochondrial enlargement

local perturbations on the integrity of the membrane that predis-

with no detrimental effects on either mitochondrial respiratory

pose to MPTP opening,49,57 although further studies are needed to

and junctional SR, when compared to wild-type cardiomyocytes.

function or LV size or function.

47

Interestingly, genetic ablation of

confirm this. The mechanisms through which partial ablation of the

cardiomyocyte-specific Mfn1 did result in smaller more fragmented

inner mitochondrial membrane fusion protein, OPA1, limits MPTP

mitochondria, but had no effect on cardiac function or mitochondrial

opening susceptibility are not clear, although it has been postu-

respiratory function, although it did prolong time to induce ROS-

lated that partial loss of OPA1 may disturb the organization of the

mediated MPTP opening.

51

The differential effects of Mfn1 versus

inter-membrane space and contact points between the outer and

Mfn2 ablation on mitochondrial size may relate to the pleiotropic

inner mitochondrial membranes, and modulate the susceptibility of

non-fusion effects of Mfn2 such as acting as a tether to the SR. 27 The

MPTP opening through this mechanism.53,54

mild phenotype observed in hearts deficient in either cardiomyocyte

In summary, genetic deletion of the mitochondrial fission (Drp1,

Mfn1 or Mfn2 suggests that these proteins have a redundant func-

Mff) or fusion proteins (Mfn2, OPA1) induce changes in mitochon-

tion. Genetic ablation of both Mfn1 and Mfn2 mid-gestation resulted

drial morphology, impair mitochondrial respiration and result in di-

in a severe cardiomyopathy at day 7 of post-natal period suggesting

lated cardiomyopathy, confirming that these proteins are essential

that the mitofusins are needed for the mitochondrial remodelling

for normal cardiac development and contractile function.

which occurs in the first week following birth.

52

Cardiomyocyte-

specific deletion of both Mfn1 and Mfn2 in the adult heart resulted
in mitochondrial fragmentation, impaired mitochondrial respiration,
a mitochondrial UFR and a dilated cardiomyopathy.39,46,50,52

2.2 | Potential mechanisms underlying IR-induced
mitochondrial fission

Although genetic deletion of OPA1 is embryonically lethal, mice
with heterozygous ablation of OPA1 survive and have enlarged

In 2006, Brady et al58 made the interesting observation that simu-

mitochondria with disorganized cristae, increased time to induce

lated ischaemia in the HL-1 cardiac cell line induced a change in mito-

MPTP opening, but had no effect on cardiac function or mitochon-

chondrial morphology from an elongated phenotype to a fragmented

drial respiration, although the hearts were more susceptible to LVH

one, a change which persisted into simulated reperfusion. Subsequent

induced by total aortic constriction.53,54 Heterozygous OPA1 mice

studies have confirmed that mitochondria undergo Drp-1-mediated

did however develop a late-onset cardiomyopathy associated with

mitochondrial fission in neonatal and adult rodent hearts.16

fragmented mitochondria with disorganized cristae, impaired mito-

The mechanisms through which IR induces mitochondrial fission

55

are not clear but a number of factors may play a role: (a) oxidative

Genetic mouse models with deletions of OMA1 and/or YME1L (the

stress—this is increased in acute myocardial IRI and is known to be an

proteases responsible for cleaving L-OPA1 to S-OPA1) have been

inducer of mitochondrial fission59; (b) p38 MAPK—pharmacological in-

used to investigate the effect of modulating myocardial OPA1 levels

hibition of p38 MAPK at reoxygenation in HL-1 cells has been shown to

on mitochondrial morphology, mitochondrial respiratory function

reverse hypoxia-induced mitochondrial fragmentation, suggesting that

and cardiac function.56 Genetic deletion of Yme1l in adult cardio-

p38 MAPK activation may in part contribute to hypoxia/reoxygen-

myocytes was shown to induce mitochondrial fragmentation (due to

ation-induced mitochondrial fission58; (c) Cdk1 and PKC-δ—these have

OMA1 cleaving L-OPA1 to S-OPA1), but did not affect mitochondrial

been shown to increase during IRI and associate with Drp1, thereby in-

56

ducing mitochondrial fission59; (d) calcium overload—this occurs in IRI

Interestingly, additional deletion of OMA1 reversed the detrimental

and has been shown to induce mitochondrial fission60; (e) calcineurin—

chondrial respiratory function and increased mitochondrial ROS.

respiration, and resulted in dilated cardiomyopathy at 20 weeks.
effects of YME1L deletion by restoring OPA1 levels.

56

These studies

support an important role for OPA1 in normal cardiac function.
It is interesting and surprising to note that genetic ablation of
16

both the mitochondrial fission protein (Drp1),

IRI has been shown to induce calcineurin activation, which is known to
dephosphorylate Drp1 at Ser637, thereby promoting translocation of
Drp1 to mitochondria to induce fission.59,61 Wang et al61 have demon-

and the mitochon-

strated that miRNA499 was shown to confer cardioprotection by pre-

drial fusion proteins (Mfn1,51 Mfn249 and OPA153,54), had the same

venting IR-induced calcineurin activation and inhibiting Drp1-mediated

effect on MPTP opening in adult cardiac mitochondria, with in-

fission; (f) SUMOylation of Drp1—it has been reported that Sentrin-

creased resistance to MPTP opening. This finding suggests that the

specific protease 3 (SENP3)-mediated deSUMOylation of Drp1 facil-

mechanisms mediating the changes in MPTP opening susceptibility

itated its binding to Mff and promoted cell death following simulated

differ between ablation of the fission proteins versus ablation of the

IRI62,63; (g) succinate—it has been shown that extracellular succinate

fusion proteins. The mechanisms through which genetic ablation of

produced during acute myocardial IRI activated GPR91 and promoted

|
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Summary of major studies investigating cardioprotection with pharmacological agents targeting mitochondrial fission proteins

Mitochondrial fission
and fusion protein

Pharmacological agent

Animal acute
myocardial IRI models

Drp1

Mdivi-1, pre-treatment

In vivo mouse heart

Reduced MI size and less
fission

Drp167

Mdivi-1, 15 min prior to
reperfusion

In vivo mouse heart

Reduced MI size, less fission,
improved mitochondrial
function

Drp181

Mdivi-1, alone or in
nanoparticles at
reperfusion

Ex vivo mouse heart

Both mdivi-1 alone or in
nanoparticles reduced MI size

Mdivi-1 delivered by
nanoparticles more
cardioprotective.

Drp181

Mdivi-1, alone or in
nanoparticles at
reperfusion

In vivo mouse heart

Mdivi-1 only reduced MI
size when delivered by
nanoparticles

Mdivi-1 delivered by
nanoparticles more
cardioprotective.

Drp180

Mdivi-1, at reperfusion

In vivo closed-chest pig
heart

No reduction in MI size or
change in mitochondrial
morphology

Underpowered study.

Drp170

Dynasore, during
reperfusion

Ex vivo mouse heart

Reduced MI size

hFis1-Drp1 interaction71

P110 in stabilization and
during reperfusion

Ex vivo rat heart

Reduced MI size

hFis1-Drp1 interaction71

P110 at reperfusion

In vivo rat heart

Reduced MI size

Drp175

Drpitor1 and Drpitor1a
pre-treatment

Ex vivo rat heart

Improved right ventricle
function, less fission and
mitochondrial ROS production

16

Cardioprotective effect

Comment

Abbreviation: MI, myocardial infarct.

mitochondrial fission by inducing the translocation of Drp1 via PKC-

a therapeutic target for cardioprotection. In this regard, it has

δ, and the phosphorylation of Mff via Erk1/264; (h) myocardial levels

been shown that acute inhibition of mitochondrial fission using

of dual-specificity protein phosphatase1 (DUSP1), an anti-apoptotic

the putative Drp1 GTPase inhibitor, mitochondrial division inhibi-

phosphatase, are reduced following acute myocardial IRI, and it has

tor 1 (mdivi-1), reduced cell death in isolated adult murine cardio-

been shown that mice overexpressing DUSP1 were protected against

myocytes subjected to simulated IRI and reduced MI size in murine

Mff-induced mitochondrial fission and BNIP-mediated mitophagy and

hearts subjected to in vivo acute myocardial IRI.16 Mdivi-1 has also

had reduced MI size, when compared to control65; (i) nuclear recep-

been shown to inhibit IR-induced mitochondrial fragmentation in

tor subfamily 4 group A member 1 (NR4A1) has been reported to be

a diabetic mouse model of acute myocardial IRI67 and inhibited

up-regulated following acute myocardial IRI and induce mitochondrial

mitochondrial fission and restored the cardioprotective effects

fission and suppress mitophagy via casein kinase2 α (CK2α)-mediated

of sevoflurane under conditions of high glucose in neonatal rat

phosphorylation of Mff and FUN14 domain-containing 1 (FUNDC1),

cardiomyocytes. 68 It has also been demonstrated that mdivi-1 re-

Mice deficient in NR4A1 were demonstrated to be pro-

duced cell death in human W8B2+ cardiac stem cells subjected to

tected against acute coronary microvascular injury and mitochondrial

simulated IRI, although in that study no beneficial effects were

dysfunction, when compared with wild-type mice.66

observed on mitochondrial morphology so the mechanisms under-

respectively.

66

In summary, a number of different factors have been shown to con-

lying the cardioprotective effect in these cells are unclear. 69 Other

tribute to the observed mitochondrial fission which occurs in response

pharmacological inhibitors of mitochondrial fission have also been

to acute myocardial IRI, thereby providing multiple therapeutic targets

shown to be cardioprotective including Dynasore (a non-specific

for inhibiting mitochondrial fission as a cardioprotective strategy.

inhibitor of dynamins),70 and P110, a peptide inhibitor that inhibits
the interaction between Drp1 and hFis.71 Importantly, pharma-

2.3 | Therapeutic targeting of the mitochondrial
fission proteins for cardioprotection

cological inhibition of mitochondrial fission at the onset of reperfusion, a clinically relevant time-point, using either P11071 or
mdivi-172 was shown to reduce MI size in small animal models of
acute myocardial IRI. In Table 1, we present a summary of the main

It has been shown in HL-1 cardiac cells that transfection with Drp1

experimental studies investigating cardioprotection with pharma-

dominant-negative mutant-induced mitochondrial elongation pre-

cological agents targeting mitochondrial fission proteins.

vented MPTP opening and reduced cell death following simulated

Recent studies suggest that mdivi-1 has off-target effects that

IRI,16 demonstrating Drp-1 mediated mitochondrial fission to be

are independent of its inhibitory effects on Drp1 GTPase activity,
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including it being a weak and reversible inhibitor of complex I, and
73

modulating mitochondrial production of ROS in neurons,

and in-

fission machinery such as P11071 may be more effective in this
large animal AMI model.

hibiting complex II, and modulating transient opening of the MPTP

The beneficial effects of inhibiting mitochondrial fission have

in isolated adult cardiomyocytes.74 Novel, more specific inhibitors

also been investigated in the coronary microvasculature following

of Drp1 itself or its interaction with its OMM receptors, Mff and

acute myocardial IRI, a neglected target for cardioprotection. 82

MiD49/MiD51, would provide more effective cardioprotection and

Melatonin, a well-established cardioprotective factor, has been

facilitate the translation of acute mitochondrial fission inhibition as

shown to reduce coronary microvascular injury, as evidenced by

a cardioprotective strategy. In this regard, Wu et al75 have identified

preserved endothelial integrity, increased endothelial nitric oxide

2 novel Drp1 inhibitors (Drpitor1 and Drpitor1a) which have been

synthase (eNOS) expression, less lumen obstruction, attenuated

shown to be more potent and specific than mdivi-1 in terms of inhib-

inflammatory cell infiltration and less endothelial cell death, find-

iting Drp1 GTPase activity (without complex I inhibition), and which

ings which were associated with reduced mitochondrial fission

conferred cardioprotection against acute IRI in the isolated perfused

and less MPTP opening in coronary endothelial cells. 83 Similarly,

rat heart when given as a pre-treatment.

the sodium-glucose cotransporter 2 (SGLT2) inhibitor, empagli-

Genetic inhibition of Drp1 using either siRNA
inant-negative K38A mutant

76

61

or Drp1 dom-

flozin 84 and Bax inhibitor 1 (BI1) 85 have been reported to reduce

has been shown to prevent trans-

coronary microvascular injury by inhibiting mitochondrial fission

location of Drp1 to mitochondria, reduce cell death in isolated

via the Syk–Nox2-Drp1 signalling pathway. Finally, mice deficient

rat cardiomyocytes subjected to IRI and reduce MI size in rat

in Mff have been reported to be protected against IRI to the cor-

hearts subjected to in vivo acute IRI. With respect to the other

onary microvasculature an effect which was attributed to less mi-

mitochondrial fission protein, Mff, it has been reported that Mff

tochondrial fission, attenuated cardiolipin oxidation and apoptosis

levels increase in neonatal rat cardiomyocytes subjected to hy-

and inhibition of MPTP opening (via blocking the oligomerization

drogen peroxide,77 and in murine hearts subjected to acute IRI.78

of VDAC1 and HK-2 separation from mitochondria) in coronary

Importantly, siRNA ablation of Mff prevented hydrogen perox-

microcirculation endothelial cells.78 These findings support the

ide-induced mitochondrial fission, and siRNA knockdown of Mff

notion that therapeutic inhibition of mitochondrial fission may

also reduced MI size in the adult mouse heart subjected to acute

accrue dual benefits against acute myocardial IRI with cytopro-

IRI.77 In addition, adult mice deficient in Mff (by gene trap) have

tective effects on both cardiomyocytes and the coronary micro-

been reported to have smaller MI size, and better cardiac function

vasculature. In other organs, such as kidney 86 and brain,18 acute

compared to wild-type mice.

78

The role of the mitochondrial fis-

IRI has also been shown to induce mitochondrial fragmentation,

sion proteins, MiD49 and MiD51 has not been studied as potential

with genetic and pharmacological inhibition of Drp1 also confer-

targets for cardioprotection, although they have been reported to-

ring protection.

gether with Drp1 to mediate mitochondrial division that is needed

In summary, experimental small animal studies have provided

for vascular smooth muscle cell proliferation in pulmonary arterial

convincing evidence that acute inhibition of mitochondrial fission

hypertension (PAH) animal models,79 positioning mitochondrial

is cardioprotective, and novel more specific inhibitors of the fission

fission as a therapeutic target for PAH.

machinery are needed to translate this therapeutic strategy for pa-

Taken together, these findings demonstrate mitochondrial fis-

tient benefit. However, although acute inhibition of mitochondrial

sion to be a target for cardioprotection in rodent models of acute

fission has been shown to be cardioprotective, chronic inhibition of

myocardial IRI, and the next step in the translational pathway is to

fission is known to be detrimental, with cardiomyocyte-specific ge-

test the efficacy of this therapeutic approach in a large animal AMI

netic deletion of Drp145 increasing susceptibility to acute myocardial

model. In this regard, a recent small pilot study has tested the car-

IRI, an observation which most likely relates to the suppression of

dioprotective effects of mdivi-1 administered as an intracoronary

mitophagy, resulting in accumulation of damaged mitochondria and

bolus immediately prior to reperfusion in the clinically relevant

the development of cardiomyopathy (see Section 3). These findings

closed-chest pig AMI model. However, it found no difference in

underscore the importance of balancing mitochondrial fusion and

MI size, LV systolic function, myocardial fibrosis or mitochondrial

fission for normal cardiac function.

morphology after 3 days reperfusion when compared to vehicle
control. 80 Potential reasons for the lack of cardioprotection include the small sample size, potential off-target effects of mdivi-1
and insufficient delivery of mdivi-1 into the ischaemic myocar-

2.4 | Other cardioprotective interventions targeting
IR-induced mitochondrial fission

dium in the first few minutes of reperfusion. In terms of the latter
issue, it has been shown that nanoparticle delivery of mdivi-1 to

A number of established cardioprotective interventions, treatments

the ischaemic heart enhanced its cardioprotective effect in terms

and factors have been shown to mediate their beneficial effects via

of MI size reduction in the murine AMI model,

81

and nanoparticle

inhibition of mitochondrial fission and preservation of mitochondrial

delivery of mdivi-1 to the ischaemic heart may be more effective

function, following acute myocardial IRI. These include (a) aerobic

in the pig AMI model. Furthermore, it would be interesting to in-

interval training87; (b) nitrite pre-treatment, which has been shown

vestigate whether more specific inhibitors of the mitochondrial

to activate PKA which in turn phosphorylates Drp1 at Ser637,
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thereby preventing IR-induced mitochondrial fission88; (c) chronic
therapy with the SGLT2 inhibitors, either empagliflozin
90

gliflozin,

89

or dapa-
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mitochondrial elongation via Mfn1, inhibit MPTP opening and protect the heart against acute IRI.102

therapies which have been shown to improve cardiovas-

In the adult heart, the effects of modulating cardiomyocyte

cular outcomes, have been demonstrated to inhibit mitochondrial

mitofusins have produced unexpected effects in terms of suscepti-

fission and reduce MI size in rodent models of acute myocardial IRI;

bility to acute IRI. Adult mouse studies have reported that isolated

(d) zinc, a known cardioprotective agent, was reported to mediate

cardiomyocytes lacking Mfn1 displayed mitochondrial fragmenta-

SUMOylation of Drp1 thereby inhibiting mitochondrial fission and

tion and were protected against hydrogen peroxide-induced MPTP

reducing MI size in the mouse heart91; (e) proto-oncogene serine/

opening and cell death.51 Similarly, cardiomyocyte-specific deletion

threonine protein kinase (PIM-1) has been shown to reduce mito-

of Mfn2 in the adult heart induced a modest LVH associated with

chondrial translocation of Drp1 and inhibit mitochondrial fission

pleomorphic enlargement of mitochondria, and inhibition of MPTP

following acute myocardial IRI92; (f) vagal nerve stimulation which

opening, and increased resistance to acute myocardial IRI.49 The

is a known cardioprotective strategy has been shown to inhibit mi-

mechanisms underlying the cardioprotective effects of individual

tochondrial fission, preserve mitochondrial function and prevent

Mfn1 and Mfn2 cardiomyocyte ablation were not clear from these

MPTP opening in acute myocardial IRI small animal models

93,94

; (g)

studies. Interestingly, it has been shown that deletion of both Mfn1

Parkinson's disease-related mitochondrial protein, DJ-195 has been

and Mfn2 in the adult heart inhibited MPTP opening and reduced MI

shown to protect the heart by regulating the SUMOylation status

size,50 a cardioprotective effect which was attributed to the pleio-

of Drp1, thereby attenuating IR-induced mitochondrial fission96; (h)

tropic non-fusion role of Mfn2 in tethering mitochondria to the sar-

ginsenoside Rg5 has been shown to activate Akt and mitochondrial

coplasmic reticulum to create localized microdomains through which

hexokinase II, thereby attenuating the translocation of Drp-1 to mi-

calcium can transit. 27,103 Depletion of cardiomyocyte mitofusins

tochondria and inhibiting fission in an isoproterenol (ISO)-induced

was demonstrated to confer cardioprotection by reducing tether-

acute myocardial IRI mouse model97; (i) isosteviol sodium, a compo-

ing of mitochondria to SR and attenuating IR-induced mitochondrial

nent of artificial sweetners, has been shown to inhibit mitochondrial

calcium overload and MPTP opening.50 Therefore, targeting Mfn2

fission and reduce MI size in the isolated guinea pig heart subjected

during acute myocardial IRI to transiently disassociate mitochondria

to acute IRI98; (j) miRNA763 has been demonstrated to inhibit Mff-

from SR may provide a novel cardioprotective strategy. In this re-

induced mitochondrial fission and reduced MI size in a mouse acute

gard, Franco et al104 have engineered cell-permeant mini-peptides

77

IRI model ; and finally (k) propofol has been reported to inhibit mi-

with the ability to destabilize the fusion-constrained conformation

tochondrial fission and reduce cell death in H9C2 cells subjected to

of mitofusin (thereby inhibiting Mfn2) and promote the fusion-per-

simulated IRI.99

missive conformation (thereby activating Mfn2), but their effect on

In summary, these studies implicate IR-induced mitochondrial
fission to be a critical mediator of cardiomyocyte death following
AMI that can be targeted indirectly via a wide variety of cardioprotective agents.

mitochondrial morphology and susceptibility to acute IRI in the adult
heart remains to be tested.
With respect to the mitochondrial fusion protein, OPA1, studies have investigated its role as a cardioprotective target, but as
with Mfn2, attributing the cardioprotective effects of OPA1 to its

2.5 | Targeting mitochondrial fusion proteins for
cardioprotection

pro-fusion function has been challenging, given its potential cardioprotective non-fusion effects on mitochondrial cristae remodelling that prevent apoptosis and facilitate the assembly of electron
transport supercomplexes and improve mitochondrial respiratory

Given the data supporting mitochondrial fission to be a key deter-

efficiency. Chen et al35 showed reduced myocardial levels of OPA1

minant of cardiomyocyte death following acute IRI, studies have

and mitochondrial fragmentation in both rat and human models

explored the effect of promoting mitochondrial fusion as a target

of heart failure, and demonstrated in H9C2 cells that simulated

for cardioprotection. However, as mentioned previously, the in-

IR reduced levels of OPA1, and siRNA ablation of OPA1 induced

terpretation of these studies can be quite challenging given the

mitochondrial fragmentation, and increased susceptibility to

pleiotropic non-fusion functions of Mfn2 and OPA1, which may

IRI. Recently, it has been shown in human atrial tissue obtained

also contribute to cardioprotection. An early study in COS-7 cells

from patients undergoing cardiac bypass surgery that myocardial

demonstrated that activating Mfn2 protected cells against apop-

L-OPA1 levels were decreased and this was associated with mito-

100

totic cell death and ROS-induced MPTP opening.

In contrast to

phagy and mitochondrial biogenesis from the IRI stress of heart

this study, it has been shown that overexpressing Mfn2 in neona-

surgery.105 Le Page et al54 have shown that OPA1± mice (which

101

In HL-1 car-

have a 30% reduction in OPA1 levels) were more susceptible to

diac cells, it has been reported that overexpressing either Mfn1 or

tal cardiomyocytes increased apoptotic cell death.

acute myocardial IRI, although this effect was not associated with

Mfn2 prevented IR-induced mitochondrial fragmentation, inhibited

changes in mitochondrial morphology, mitochondrial respiratory

MPTP opening and reduced cell death following simulated IRI.16

function, apoptosis or MPTP opening, and so the mechanisms un-

In addition, activation of the cardioprotective kinase, Akt, by ei-

derlying this cardioprotective effect are not clear from this study.

ther genetic activation or erythropoietin has been shown to induce

In contrast, it has been shown in the adult mouse that genetic
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overexpression of OPA1 stabilized mitochondrial cristae thereby

energy substrates, removes damaged mitochondria and attenuates

improving mitochondrial respiratory efficiency, preventing mito-

oxidative stress. In this regard, it has been shown that inhibition of

chondrial dysfunction, attenuating cytochrome c release and ROS

mitophagy in mice deficient in cardiomyocyte Drp145 or PGAM5114

production, and through these actions, it reduced susceptibility

or treatment with bicarbonate115 increased cell death following

to acute myocardial IRI.106 However, the effect of OPA1 overex-

acute IRI. In contrast, activation of mitophagy prior to acute myo-

pression on preventing IR-induced mitochondrial fragmentation

cardial ischaemia, by cardioprotective strategies such as ischaemic

was not assessed, as the cardioprotective effects of OPA1 were

preconditioning116 and simvastatin,117 has been shown to reduce

attributed to its non-fusion effects on mitochondrial cristae re-

myocardial infarction size following acute myocardial IRI. It has also

modelling and improving mitochondrial respiratory efficiency.

been shown that mitophagy activation occurs in human heart tis-

Importantly, in this mouse model of OPA1 overexpression, there

sue harvested from patients subjected to acute myocardial IRI dur-

were beneficial effects in other organs with protection from mus-

ing cardiac surgery and is associated with increases in mitochondrial

cular atrophy, brain ischaemia and liver apoptosis.106

biogenesis, where it promotes turnover of cardiac mitochondria.105

Interestingly, the role of OPA1 as a cardioprotective target has been

The canonical PINK-Parkin pathway for homeostatic mito-

investigated in the context of remote ischaemic conditioning (RIC), an

phagic mitochondrial quality control was originally defined by

endogenous cardioprotective strategy in which cycles of brief non-le-

genetic manipulation of these two factors in Drosophila fruit

thal ischaemia and reperfusion applied to the limb increase resistance

flies,118,119 establishing the mitophagy mechanistic link between

to a sustained episode of lethal acute myocardial IRI.107-109 These au-

the mitochondria-localized kinase, PINK and the downstream cy-

thors showed that using a tourniquet to induce four- to 5-minute cycles

tosolic E3-ubiquitin ligase, Parkin (Figure 2). Contrasting with the

of hindlimb ischaemia and reperfusion reduced MI size, and this was

situation in normal hearts wherein Parkin is barely detectable and

associated with less mitochondrial fragmentation and preservation of

functionally dispensable, Parkin is transcriptionally up-regulated in

myocardial OPA1 levels without affecting levels of Mfn2.109 Further

different forms of cardiac stress where it plays an important role

studies are needed to investigate whether RIC increased myocardial

in the mitophagic response.46,120,121 Compared to wild-type mice,

OPA1 levels by suppressing stress-induced activation of OMA1. The

Parkin-deficient mice had disorganized mitochondrial networks and

cardioprotective agent, melatonin, has recently been demonstrated

smaller mitochondria, although mitochondrial and cardiac function

to confer cardioprotection via AMPK-OPA1 as evidenced by reduced

were unaffected.120 However, the Parkin-/- mice were more sus-

MI size, inhibition of IR-induced mitochondrial fission, preservation of

ceptible to acute myocardial IRI and had reduced survival and mi-

mitochondrial respiratory function, less MPTP opening and decreased

tophagy with accumulated swollen, dysfunctional mitochondria

apoptosis.110 Similarly, the brain-derived neurotrophic factor mimetic,

after infarction.120 In contrast, overexpression of Parkin in isolated

7,8-dihydroxyflavone, has been reported to confer cardioprotec-

cardiomyocytes protected against simulated ischemic injury.120 A

tion via inhibition of IR-induced mitochondrial fission and decreased

cardioprotective role for PINK1 kinase has also been observed in a

apoptosis.111 Finally, modulation of OPA1 levels by genetic ablation of

mouse AMI model.122 These data suggest cardioprotective effects

OMA1 has also been shown to protect against acute renal IR acute in-

of the PINK-Parkin mitophagy pathway in the setting of acute myo-

jury.112 In terms of therapeutic targeting of OPA1 as a cardioprotective

cardial IRI.

strategy, a recent study has identified epigallocatechin gallate to be a

Drp1-mediated mitochondrial fission generates fragmented

novel pharmacological inhibitor of OMA1. Treatment of mouse embry-

mitochondria for selective removal by Parkin-induced and Bnip3-

onic fibroblasts was able to prevent cleavage of L-OPA1 to S-OPA1,

induced mitophagy123,124 as a key strategy for maintaining mitochon-

inhibit mitochondrial fission, prevent apoptosis and reduce cell death

drial quality control. It has been shown that siRNA ablation of Drp1

following simulated IRI, providing a potential therapeutic strategy for

in neonatal ventricular rat cardiomyocytes induced mitochondrial

reducing MI size following acute myocardial IRI.

elongation, increased apoptosis, suppressed autophagic flux, result-

In summary, these studies implicate the mitochondrial fusion

ing in accumulation of dysfunctional mitochondria and increased

proteins, Mfn2 and OPA1, to be potential targets for cardioprotec-

MPTP opening.45 Overexpression of Drp1 in cardiomyocytes in-

tion, but the mechanisms underlying their beneficial effects appear

duced mitochondrial fragmentation, enhanced autophagic flux and

to be related to their non-fusion pleiotropic functions rather than

increased apoptotic cell death.45 Cardiomyocyte-specific ablation

their pro-fusion effects.

of Drp1 in adult mice at 12 weeks of age induced cardiomyocyte
hypertrophy and a lethal dilated cardiomyopathy with mitochondrial

3 | TA RG E TI N G M ITO PH AG Y FO R
C A R D I O PROTEC TI O N

elongation, increased apoptosis, suppressed autophagic flux, accumulation of dysfunctional mitochondria and increased MPTP opening.45 Interestingly, both heterozygous Drp1 mice and mice with
cardiomyocyte-specific ablation of Drp1 in adult mice increased MI

Under basal conditions, mitophagy is required for mitochondrial

size, suggesting that chronic Drp1 ablation and perturbed mitophagy

quality control and plays a key role in removal of damaged mitochon-

increases susceptibility to acute myocardial IRI,45 which differs from

113

dria.

Mitophagy is activated during acute myocardial IRI, where

it appears to protect the heart against cell death, as it preserves

acute inhibition of mitochondrial fission which has been shown to be
cardioprotective.16
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Mfn2 involvement in mitophagy is contextually complex, re-

cell death. It has been shown that Mfn2 regulates the UPR and mi-

cruiting Parkin to mitochondria for normal perinatal metabolic

tochondrial respiratory function by down-regulating protein kinase

remodelling, 28,125 controlling mitochondrial quantity in normal

RNA-like endoplasmic reticulum kinase (PERK), an ER stress-related

adult hearts46,126 and mediating stress-induced calcium signalling

protein.132 Adult mice deficient in cardiomyocyte Mfn2 have also

between cardiomyocyte ER and mitochondria.127-129 How these

been shown to have increased ER stress (as evidenced by increased

different mechanisms of mitofusin-involved mitophagy overlap,

expression of ER stress-related genes Asns, Atf4, Trib3, Chop, ATF6,

complement or compete with each other and with other mitophagy

and Gsta1), supporting a role for Mfn2 in preventing ER stress in the

pathways remains incompletely understood. Interestingly, Mfn2 has

adult heart. 29 The role Mfn2 plays specifically in UPRmt remains to

also be reported to be required for cardiac autophagy, by potentially

be established. The UPRmt has recently been demonstrated to occur

functioning as an adaptor on ER-derived autophagosome membrane

in heart diseases such as cardiac failure,133 pressure overload134 and

for RAB7, a autophagosome maturation-related protein, to mediate

acute myocardial IRI,5 making it an attractive therapeutic target for

the fusion of autophagosomes with lysosomes.

29

Mice deficient in

cardioprotection.

cardiomyocyte Mfn2 were shown to accumulate autophagosomes

It has been shown in mice hearts subjected to pressure-over-

due to impaired fusion of autophagosomes with lysosomes, resulting

load hypertrophy and in hypertrophied human heart tissue due

in impaired mitochondrial function, slightly enlarged mitochondria

to aortic stenosis, that the UPR mt is increased as evidenced by

and increased susceptibility to acute myocardial IRI,

29

suggesting an

up-regulation of ATF5 and the C/EBP transcription factor CCAT-

important role for Mfn2-mediated autophagy as a cardioprotective

enhancer-binding protein homologous protein (CHOP), which

target.

encodes adaptive proteins of the UPR mt .134 Importantly, from a

Recently, a novel PINK/Parkin-independent pathway of mi-

therapeutic perspective, it was reported that the UPR mt could

tophagy has been described which functions under conditions

be enhanced using nicotinamide riboside (which augments NAD +

of energy stress including starvation and acute myocardial IRI130

pools) in cardiomyocytes and prevented cardiomyocyte death

(Figure 2). This is based on a protein complex consisting of unc-51-

and preserved mitochondrial respiratory function and cardiac

like kinase 1 (Ulk1), Rab9, receptor-interacting serine/threonine

contractile function.134 Pharmacological induction of the UPR mt

protein kinase 1 (RIP1) and Drp1, which allows the recruitment

using either oligomycin or doxycycline reduced MI size in wild-

of trans-Golgi membranes associated with Rab9 to damaged mi-

type mice but not ATF5-deficient mice, suggesting that ATF5-

tochondria through phosphorylation of Rab9 at S179 by Ulk1

mediated UPR mt confers cardioprotection against acute IRI. 5 The

130

This novel

mitochondrial protease, LonP1, which ensures mitochondrial pro-

Ulk1/Rab9/Rip1/Drp1 mitophagy pathway was shown to protect

and phosphorylation of Drp1 at S616 by RIP1.

teostasis and regulates adaptive responses to cell stress, has been

the heart against acute myocardial IRI by maintaining healthy

shown to contribute to the cardioprotection elicited by ischaemic

130

mitochondria.

preconditioning (IPC), an endogenous cardioprotective interven-

In summary, enhancing mitophagy during acute myocardial IRI is

tion in which brief cycles of non-lethal ischaemia and reperfusion

an important strategy for cardioprotection. Given the close interplay

protect the heart against an episode of acute lethal IRI.135 IPC

between mitochondrial morphology and mitophagy, therapeutic tar-

was shown to up-regulate LONP1 in wild-type mice, and hetero-

geting of the mitochondrial fission and fusion proteins may provide a

zygous LONP1± mice were shown to be more susceptible to acute

strategy for boosting mitophagy following AMI.

myocardial IRI as evidenced by mitochondrial dysfunction and increased MI size, and were found to be resistant to IPC-induced

4 | TA RG E TI N G TH E M ITO C H O N D R I A L
U N FO LD E D PROTE I N R E S P O N S E FO R
C A R D I O PROTEC TI O N

cardioprotection.136 In contrast, genetic overexpression of cardiomyocyte-specific LONP1 prevented IR-induced mitochondrial dysfunction and reduced MI size, implicating mitochondrial
LONP1 as an endogenous mediator of cardioprotection.136
In summary, enhancing the UPRmt during acute myocardial IRI

mt

The mitochondrial UPR (UPR ) is a cytoprotective signalling path-

has emerged as a novel therapeutic cardioprotective strategy.

way triggered by the mitochondrial accumulation of toxic unfolded

Although pharmacological strategies such as nicotinamide riboside,

proteins under conditions of cellular stress that induces mitochon-

oligomycin and doxycycline have been shown to confer cardiopro-

drial dysfunction (Figure 3). The UPRmt, in turn, up-regulates cy-

tection by enhancing the UPRmt, novel more specific activators of

clic AMP-dependent transcription factor ATF-5 (ATF5) to restore

the UPRmt are needed.

131

mitochondrial proteostasis and respiratory function.

The mito-

chondrial fusion protein, Mfn2, which is known to tether mitochondria to the ER, has been shown to regulate the UPR. Ngoh et al30

5 | CO N C LU S I O N S

showed that ER stress induced the gene and protein expression of
Mfn2 but not Mfn1, with ablation of Mfn2 (but not Mfn1) in adult

Preventing mitochondrial dysfunction during acute myocardial IRI

murine cardiomyocytes exacerbating ER stress-mediated apoptotic

following AMI is a major therapeutic strategy for cardioprotection
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in terms of reducing MI size, preserving cardiac function and preventing the onset of HF. In this regard, the mitochondrial fission
and fusion proteins which play key roles in process involved in
mitochondrial quality control (such as mitochondrial morphology,
mitophagy and UPR mt), act to preserve normal mitochondrial respiratory function in the setting of acute myocardial IRI, positioning
them as key targets of cardioprotection. Substantial experimental
data suggest that acute inhibition of mitochondrial fission can reduce MI size and preserve cardiac function in small animal models
of AMI. Further studies are needed to test this therapeutic approach in clinically relevant large animal AMI models and to discover novel more specific inhibitors of the mitochondrial fission
machinery. However, it is important to note that chronic inhibition of mitochondrial fission is detrimental to both susceptibility
to acute IRI and cardiac function, as it suppresses mitophagy and
results in the accumulation of damaged mitochondria. Although
the mitochondrial fusion protein, OPA1, has been shown to be
a target for acute cardioprotection (with its overexpression protecting against acute myocardial IRI), its beneficial effects have
been attributed to non-fusion pleiotropic roles rather than its
effects on mitochondrial morphology. The role of the mitofusins
as targets for acute cardioprotection has been unexpected, as it
appears that ablation of Mfn1 and/or Mfn2 confers a protective
response against acute myocardial IRI, and again this may be due
to their non-fusion pleiotropic roles (such as tethering SR), rather
than their effects on mitochondrial morphology. Overall, targeting the mitochondrial fusion and fission proteins have emerged as
important targets for cardioprotection and have the therapeutic
potential to reduce MI size, preserve cardiac function and prevent
HF in patients presenting with AMI.
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